Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody (Q59353967)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

title

Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

4

Paul Dent

0 references

author name string

Laurence Booth

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Jane Lisa Roberts

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Andrew Poklepovic

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Paul Dent

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

language of work or name

English

0 references

publication date

24 August 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

Cancer Biology and Therapy

19 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

page(s)

109-121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle

19 April 2020

cites work

1 reference

12 December 2020

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

1 reference

12 December 2020

The third 20 amino acid repeat is the tightest binding site of APC for beta-catenin

1 reference

12 December 2020

beta-catenin destruction complex: insights and questions from a structural perspective

1 reference

12 December 2020

Terminal regions of beta-catenin come into view

1 reference

12 December 2020

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

1 reference

12 December 2020

Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

1 reference

12 December 2020

Wnt/beta-catenin signaling: components, mechanisms, and diseases

1 reference

12 December 2020

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors

1 reference

12 December 2020

Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway

1 reference

12 December 2020

Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating β-catenin

1 reference

12 December 2020

Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer

1 reference

12 December 2020

Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts.

1 reference

12 December 2020

Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer

1 reference

12 December 2020

Immune effectors required for the therapeutic activity of vorinostat

1 reference

12 December 2020

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.

1 reference

12 December 2020

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo

1 reference

12 December 2020

[pemetrexed + sildenafil], via autophagy-dependent HDAC down-regulation, enhances the immunotherapy response of NSCLC cells

1 reference

12 December 2020

Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges.

1 reference

12 December 2020

HDAC inhibitors enhance the immunotherapy response of melanoma cells

1 reference

12 December 2020

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

1 reference

12 December 2020

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

1 reference

12 December 2020

Discovery of IDO1 Inhibitors: From Bench to Bedside

1 reference

12 December 2020

HDAC inhibition potentiates immunotherapy in triple negative breast cancer

1 reference

12 December 2020

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells

1 reference

12 December 2020

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.

1 reference

12 December 2020

Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer

1 reference

12 December 2020

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer

1 reference

12 December 2020

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration

1 reference

12 December 2020

Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?

1 reference

12 December 2020

TUMOR CROSSTALK NETWORKS PROMOTE GROWTH AND SUPPORT IMMUNE EVASION IN PANCREATIC CANCER.

1 reference

12 December 2020

Cancer immunotherapy using checkpoint blockade.

1 reference

12 December 2020

Targeting Macrophages in Cancer: From Bench to Bedside.

1 reference

12 December 2020

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.

1 reference

12 December 2020

Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.

1 reference

12 December 2020

Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors.

1 reference

12 December 2020

MHC class I presented antigens from malignancies: A perspective on analytical characterization & immunogenicity.

1 reference

12 December 2020

Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends

1 reference

12 December 2020

Immunotherapy in mucosal melanoma: a case report and review of the literature.

1 reference

12 December 2020

Combination Immunotherapy in Non-small Cell Lung Cancer

1 reference

12 December 2020

Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages.

1 reference

12 December 2020

KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation

1 reference

12 December 2020

10.1080/15384047.2018.1507258

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30142009%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

PubMed publication ID

30142009

1 reference